Toward vaccines against cervical cancer

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 2, 2004, Pages 228-232

  Jansen, Kathrin U ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Prophylactic papillomavirus vaccine; Virus like particles

Indexed keywords

CANCER VACCINE; VIRUS VACCINE;

CANCER RESEARCH; CELL CYCLE REGULATION; CELL TRANSFORMATION; DRUG RESEARCH; HUMAN; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; UTERINE CERVIX CANCER; VIRUS GENOME; WART VIRUS; ANIMAL; FEMALE; IMMUNOLOGY; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ANIMALS; CANCER VACCINES; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 16644391629     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Ferlay J, Bray F, Pisani P, Parkin DM (Eds): Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC Press, Lyons, France (2001).
2. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J: Human papillomavirus testing in primary cervical screening. Lancet (1995) 345(8964):1533-1536.
3. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med (2000) 132(10):810-819.
4. Ratnam S, Franco EL, Ferenczy A: Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev (2000) 9(9):945-951.
5. Zur Hausen H, de Villiers EM, Gissmann L: Papillomavirus infections and human genital cancer. Gynecol Oncol (1981) 12(2 Pt 2):S124-S128.
6. International Agency for Research on Cancer: Human papillomaviruses (HPV). In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans and their Supplements, Volume 64. IARC Press Lyons, France (1995). Review of evidence that certain papillomaviruses cause cervical cancer and should therefore be considered human carcinogens.
7. Bosch FX, Lorincz A, Munoz N, Meijer C, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 55(4):244-265.
8. Howley PM: Papillomaviridae: The viruses and their replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM, Chanock KM, Melnick JL, Monath TD, Roizman B, Straus SE (Eds), Lippincott-Raven, Philadelphia, PA, USA (1996):2045-2076.
9. Jarrett WF, Murphy J, O'Neil BW, Laird HM: Virus-induced papillomas of the alimentary tract of cattle. Int J Cancer (1978) 22(3):323-328.
10. Kreider JW: Neoplastic progression of the Shope rabbit papilloma. In: Viruses in Naturally Occurring Cancers. Essex M, Todaro G, Hausen zur H (Eds), CSH Press, Cold Spring Harbor, NY, USA (1980):283-299.
11. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer C: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med (2003) 348(6):518-527.
12. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer C: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet (1599) 354(9172):20-25.
13. Christensen ND, Kreider JW: Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol (1990) 64(7):3151-3156. Article reporting that HPV capsids carry neutralizing epitopes.
14. Zhou J, Sun XY, Stenzel DJ, Frazer IH: Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology (1991) 185(1):251-257. First report of a study demonstrating that HPV VLPs can be expressed recombinantly and that expression of capsid proteins form virus-like particles. This finding prepared the field for the development of prophylactic HPV vaccines.
15. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, DeGrandi P: Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun (1997) 65(8):3328-3336.
16. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA (1992) 89(24):12180-12184.
17. Rose RC, Bonnez W, Reichman RC, Garcea RL: Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles. J Virol (1993) 67(4):1936-1944.
18. Hofmann KJ, Cook JC, Joyce JG, Brown DR, Schultz LD, George HA, Rosolowsky M, Fife KH, Jansen KU: Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology (1995) 209(2):506-518.
19. Hagensee ME, Yaegashi N, Galloway DA: Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol (1993) 67(1):315-322.
20. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford L, Tommasino M: Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology (1995) 206(1):126-135.
21. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Muller M: Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol (2003) 77(17):9211-9220.
22. Chen XS, Casini G, Harrison SC, Garcea RL: Papillomavirus capsid protein expression in Escherichia coli. Purification and assembly of HPV11 and HPV16 L1. J Mol Biol (2001) 307(1):173-182.
23. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, Martinez D, Ellis RW, Shaw AR: Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine (1995) 13(16):1509-1514.
24. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR: Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 69(6):3959-3963.
25. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA (1995) 92(25):11553-11557.
26. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 219(1):37-44.
27. Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang LY, Chen L, Cook JC, McClements WL, Jansen KU: Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine (2003) 21(13-14):1539-1547. Comprehensive study in rhesus monkeys comparing different vaccine delivery systems to evaluate humoral and cell-mediated responses using HPV-16 L1 as a model antigen.
28. Palker TJ, Monteiro JM, Martin MM, Kakareka C, Smith JF, Cook JC, Joyce JG, Jansen KU: Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine (2001) 19(27):3733-3743.
29. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J et al: Safety and immunogeniclty trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 93(4):284-292. First published study demonstrating that immunization with HPV-16 VLPs expressed in insect cells induces high titered neutralizing antibody responses in humans.
30. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC: A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis (2001) 183(10):1485-1493. First published study demonstrating that immunization with HPV-11 VLPs expressed in insect cells induces high titered neutralizing antibody responses in humans.
31. Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, Barr E, Smith PR, Chiacchierini L, DiCello A, Jansen KU: Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer. J Infect Dis (2001) 184(9):1183-1186. First published study demonstrating that immunization with HPV-11 VLPs expressed in yeast induces high-titered neutralizing antibody responses in humans.
32. Brown DR, Fife KH, Wheeler CM, Koustky LA, Lupinacci LM, Railkar R, Suhr G, Barr E, DiCello A, Li W, Smith JF et al: Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine (2004): in press.
33. Fife K, Wheeler C, Koutsky L, Barr E, Brown D, Schiff M, Kiviat N, Jansen K, Barber H, Smith J, Suhr G et al: Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine (2004): in press. First clinical report showing that antibody responses to HPV-16 and -11 VLPs expressed in yeast persisted in the vast majority of immunized individuals (over a 36-month study).
34. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. N Eng J Med (2002) 347(21):1645-1651. First report of a randomized, placebo-controlled trial demonstrating that systemic immunization with an HPV VLP-based vaccine was 100% efficacious in protecting young women against HPV infection and disease.
35. Vaccines and related biological products advisory committee: Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, MD, USA. http://www.fda.gov/ohrms/dockets/ac/01/minutes/3805m1.pdf
36. Dubin G: Development of an adjuvanted human papillomavirus type 16/18 L1 virus like particle vaccine. Eurogin 2003. Paris, France (2003): Abs SS20-05.
37. Anonymous: Sexually transmitted infections quarterly report: Anogenital warts and HSV infection in England and Wales. CDR Weekly (2001) 11(35):11-15.
38. Bottiger M, Forsgren M: Twenty years' experience of rubella vaccination in Sweden: 10 Years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine (1997) 15(14):1538-1544.
39. Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. J Am Med Assoc (2003) 290(6):781-789. Outcome of mathematical modeling showing that introduction of a prophylactic HPV vaccine is cost-effective in conjunction with screening.
40. Hughes JP, Garnett GP, Koutsky L: The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology (2002) 13(6):631-639.